BiotechTube
Editas Medicine

Editas Medicine

EDIT
Cambridge, United States· Est.
editasmedicine.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

EDIT · Stock Price

USD 3.03+1.58 (+108.97%)
Market Cap: $300.6M

Historical price data

Overview

Editas Medicine is a clinical-stage leader in CRISPR-based gene editing, founded in 2013 and headquartered in Cambridge, Massachusetts. The company's strategy centers on developing in vivo gene editing medicines, with its most advanced program, EDIT-401 for hyperlipidemia, poised for human proof-of-concept by end of 2026. While facing a competitive landscape and significant clinical and financial risks, Editas possesses foundational IP and a differentiated platform that could yield best-in-class, potentially curative therapies.

CardiovascularHematologyOncology

Technology Platform

Proprietary dual-nuclease CRISPR platform utilizing both Cas9 and Cas12a (Cpf1) systems for in vivo gene editing, enabling a broad range of DNA targeting and repair mechanisms.

Pipeline

1
1 drug in pipeline
DrugIndicationStageWatch
EDIT-101Leber Congenital Amaurosis 10Phase 1/2

Opportunities

EDIT-401 addresses a multi-billion dollar market in hyperlipidemia/ASCVD with potential for best-in-class, one-time efficacy.
Successful in vivo platform validation could be applied to numerous other genetic diseases.
Strategic partnerships provide non-dilutive funding and de-risk oncology efforts.

Risk Factors

High clinical risk as lead program is preclinical; failure in human trials would be catastrophic.
Severe financial constraints and low valuation limit options and necessitate dilutive financing.
Intense competition from better-funded rivals with advanced clinical programs.

Competitive Landscape

Faces direct competition from Intellia Therapeutics and Verve Therapeutics in in vivo editing for cardiovascular disease, and from CRISPR Therapeutics/Vertex in hemoglobinopathies. Differentiation hinges on demonstrating superior efficacy (e.g., 90% LDL-C reduction) and leveraging its dual-nuclease platform.

More companies in CRISPR / Gene Editing →More companies in United States →